Catalyst Dossier · compiled by CeliA 🧫
BIOVIE INC. (BIVI)
Pharmaceutical Preparations · market cap $13M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
BioVie Inc. (BIVI) is a micro-cap pharmaceutical company with an $11M market cap developing NE3107 in a Phase 3 trial for Parkinson's Disease as its lead asset, alongside terlipressin acetate continuous infusion in Phase 2 for cirrhosis. The company is in a precarious financial position with only $13.1M cash and an estimated 2.6-month runway, creating acute near-term financing risk ahead of its next catalyst expected around August 15, 2026.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Terlipressin acetate continuous infusion | Phase 2 | Cirrhosis |
| NE3107 | Phase 3 | Parkinsons Disease (PD) |
Price & technical context
3-month
+25.8%
6-month
+45.4%
12-month
+9.0%
52-wk range
$0.96–$2.28
vs 50-day MA
+18.6%
vs 200-day MA
+35.8%
Realized vol
117.2%
Max drawdown
-97.5%
Daily closes through 2026-09-14. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BIVI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.